Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities
Status:
Withdrawn
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This community-based cluster Randomised Control Trial will assess the feasibility, cost,
risks and benefits of use of oral Misoprostol and parenteral Oxytocin in Uniject® as
prophylaxis for postpartum hemorrhage (PPH) in community settings. The study will be
conducted in Jamnagar district in Gujarat state in India. The hypothesis is that a program to
deliver oral misoprostol and one to deliver oxytocin via Uniject® will both be effective in
preventing PPH when introduced in community-based settings.
Phase:
Phase 3
Details
Lead Sponsor:
Gynuity Health Projects
Collaborators:
Aga Khan Health Services Department of Health and Family Welfare, Government of Gujarat